FucoID Technology Platform for Identifying Tumor Antigen-Specific T Cells

Introduction Featured Services Advantages Applications FAQs Resources Related Sections

The reactivation and clonal expansion of tumor-specific antigen (TSA)-reactive T cells are critical to the success of tumor-infiltrating lymphocyte (TIL)-based therapies. In many emerging personalized cancer therapies, the key to success is to find the elusive TSA-reactive T cells, then create more of these cells outside the patient's body, and then reintroduce them for tumor treatment. However, an unmet need in this field is the ability to identify useful tumor-infiltrating immune cells more quickly and accurately. Due to its heterogeneous composition, there is no reliable marker that can specifically identify the composition of TSA-responsive T cells.

At Creative Biolabs, we have developed a new technology, FucoID, named after the enzyme fucosyltransferase, which plays a key role in "labeling" the surface of the desired immune cells so that they can be seen and captured. Through this interaction-dependent labeling method, the universal FucoID platform can detect endogenous antigen-specific T cells to study their biological characteristics. Featuring genetic manipulation-free and fast turnover cycle characteristics, FucoID should have the potential to accelerate the pace of personalized cancer treatment.

FucoID Platform: A Fast, Precise Tool Identifies Tumor-Targeting T Cells

FucoID, tumor-lysate primed DCs presenting TSAs, acts as a "living" tetramer, equipped with an enzyme that induces proximity-based transfer of fucosylated biotin (Fuc-Bio) tags to the surface of T cells that interact with the DCs. Specifically, the enzyme is loaded on dendritic cells, which are immune cells that can present tumor-specific substances to the required T cells. When cells interact, enzymes transfer tags to anti-tumor cells, so scientists can detect them with fluorescent probes and extract them from samples.

Fucosyl-Biotinylation for Cell Interaction Tracking. Fig.1 Interaction-Dependent Fucosyl-Biotinylation Was Used for Tracking Direct Cell-Cell Interactions.¹

Features of Our FucoID Platform

Here at Creative Biolabs, we're thrilled to introduce the FucoID Technology Platform that provides unrivaled precision and tempo for research on tumor immunology. Our approach to cancer-specific T cell discovery is new and transformative for researchers.

Accurate Detection of Endogenous Tumor Antigen-Specific T Cells

By using our proprietary fucosyl-biotinylation technology, Creative Biolabs guarantees the accurate expression of tumor antigen-specific T cells present in the bloodstream, allowing scientists to gain essential knowledge about the immune microenvironment of the tumor.

Genetic Manipulation-Free and Reliable

Creative Biolabs has developed a platform that eliminates the need for genetic modifications, maintaining the integrity of immune cells while enhancing reliability and scalability in diverse applications.

Swift Identification and Quantification of TSA-Reactive T Cells

With FucoID, Creative Biolabs enables rapid and efficient profiling of tumor-specific T cells directly from patient samples, accelerating the journey toward personalized cancer therapies.

Efficiency Beyond Traditional Methods

Powered by interaction-dependent labeling and cutting-edge bioinformatics, FucoID provides a faster and more effective alternative to conventional techniques, ensuring quick turnaround times and highly reproducible results.

Talk to an Expert →

How FucoID Outperforms Traditional Methods

At Creative Biolabs, our FucoID Technology Platform represents a significant leap forward in the identification and isolation of tumor-specific T cells, setting a new benchmark for speed, precision, and reliability in tumor immunology research. Unlike traditional methods, FucoID addresses critical limitations while enhancing research and clinical outcomes.

	FucoID Technology	Traditional Methods
Detection Mechanism	Interaction-dependent labeling for precise TSA-reactive T cell tagging.	Indirect assays with lower accuracy.
Genetic Modifications	Genetic manipulation-free, preserving cell integrity.	Requires genetic engineering, altering cell properties.
Speed	Rapid profiling with quick turnover.	Time-intensive processes.
Scalability	Easily scalable for high-throughput studies.	Resource-intensive, limiting scalability.
Reliability	High reproducibility with consistent results.	Greater variability in outcomes.
Innovation	Advanced bioinformatics and fucosyl-biotinylation integration.	Relies on conventional, less precise techniques.

Applications

At Creative Biolabs, we are proud to offer the innovative FucoID Technology Platform, a powerful tool that is transforming tumor immunology research. Designed with precision and efficiency in mind, FucoID enables researchers to unravel the complexities of immune responses in cancer, unlocking new avenues for scientific discovery.

Insights into Tumor-Specific T Cell Biology

Creative Biolabs leverages FucoID technology to provide researchers with unparalleled capabilities for studying tumor-specific antigen (TSA)-reactive T cells. By examining their activation, proliferation, and effector mechanisms, researchers can gain a deeper understanding of the dynamic roles these cells play within the tumor microenvironment.

HTS with Unmatched Accuracy

With FucoID, Creative Biolabs empowers researchers to perform high-throughput screening of TSA-reactive T cells, ensuring the identification of key populations with exceptional precision and reproducibility. This streamlined process accelerates the pace of discovery and enables robust data generation.

Advanced Mapping of the Tumor Microenvironment

Our technology enables the detailed mapping of immune cell interactions within the tumor microenvironment. FucoID helps researchers uncover critical mechanisms of immune evasion and tumor progression, providing data essential for advancing the field of cancer immunology.

Enhanced Immune Checkpoint Research

FucoID's precise identification of T cells interacting with immune checkpoints allows researchers to explore the intricate pathways governing immune regulation. This capability supports groundbreaking studies into immune modulation in the tumor microenvironment. For more solutions, discover our immune checkpoint assays.

Facilitating Neoantigen Discovery

At Creative Biolabs, we recognize the importance of neoantigens in cancer research. FucoID's ability to isolate tumor-specific T cells interacting with antigen-presenting cells aids in the discovery of novel neoantigens, paving the way for new insights into tumor immunogenicity and immune targeting strategies.

FucoID technology eliminates important obstacles to the study of tumor-specific T cells and will be very useful to both basic scientists and clinicians. If you are interested in our services, please send an email to contact us, and our team will get back to you as soon as possible.

FAQs

Can FucoID technology be integrated with other immunotherapy platforms?

FucoID can complement a variety of immunotherapy platforms, such as CAR-T cell development, immune checkpoint assays, and neoantigen discovery. This integration enhances the efficiency of developing personalized therapies by streamlining T cell isolation and validation processes.

How does FucoID technology specifically identify TSA-reactive T cells without genetic manipulation?

FucoID employs interaction-dependent labeling by loading dendritic cells (DCs) with tumor-specific antigens and the enzyme fucosyltransferase. When TSA-reactive T cells interact with these DCs, the enzyme transfers biotin-labeled fucosyl groups to the T cells, enabling precise identification without altering cellular genetic structures.

What are the limitations of FucoID technology in current research applications?

While FucoID excels in precision and speed, its effectiveness can be influenced by sample quality and the efficiency of dendritic cell priming. Additionally, its use in highly heterogeneous tumor microenvironments may require further optimization to ensure comprehensive detection of all TSA-reactive T cells.

Can FucoID technology be applied to rare tumor types or less common cancers?

Yes, FucoID is adaptable to a wide variety of cancer types, including rare malignancies, by customizing dendritic cell priming with tumor-specific lysates. This flexibility allows researchers to isolate TSA-reactive T cells even in unique or underexplored tumor contexts.

What quality control measures are in place for FucoID-based analyses?

FucoID workflows incorporate rigorous quality checks, including validation of dendritic cell antigen loading, verification of enzymatic activity, and fluorescence-based assays to ensure accurate labeling. These measures guarantee reproducibility and reliability in both research and clinical settings.

How does FucoID handle TSA-reactive T cells in highly immunosuppressive environments?

FucoID is designed to work effectively even in challenging immunosuppressive environments by focusing on direct cell-cell interactions. The use of tumor-lysate primed dendritic cells ensures robust antigen presentation, enabling the identification of reactive T cells despite immune suppression.

What downstream analyses can be performed on TSA-reactive T cells isolated by FucoID?

Isolated TSA-reactive T cells can undergo functional assays, TCR sequencing, transcriptomic profiling, and cytotoxicity testing. These analyses provide insights into T cell behavior, clonality, and therapeutic potential. Learn more about immune cells function assay.

What types of samples are compatible with the FucoID platform?

FucoID is compatible with a wide range of samples, including fresh tumor biopsies, cryopreserved tissues, and peripheral blood mononuclear cells (PBMCs). Each sample type undergoes tailored preparation protocols to ensure optimal antigen presentation and cell labeling.

Reference

An, Liwei, et al. "Decoding the intercellular communication network during tumorigenesis." Cancer Biology & Medicine 19.3 (2021): 265. Distributed under Open Access license CC BY 4.0, without modification.